<DOC>
	<DOCNO>NCT02300298</DOCNO>
	<brief_summary>To determine appropriateness dose nintedanib 200 mg b.i.d . plus docetaxel 75 mg/m2 start dose evaluate safety Japanese patient body surface area ( BSA ) &lt; 1.5 m2 locally advance metastatic adenocarcinoma subtype non-small cell lung cancer ( NSCLC ) failure first line platinum- base chemotherapy</brief_summary>
	<brief_title>Nintedanib Plus Docetaxel Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure First Line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients age 20 year old date inform consent 2 . Patients BSA &lt; 1.5 m2 screen 3 . Patients histologically/cytologically confirm locally advanced metastatic adenocarcinoma subtype NSCLC failure first line platinumbased chemotherapy ( patient nontarget lesion eligible ) First line chemotherapy may include continuation switch maintenance therapy . One prior adjuvant and/or neoadjuvant chemotherapy accept . 4 . Patients life expectancy least 3 month 5 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 screen 6 . Patients obtain write informed consent accordance ICHGCP Japanese GCP Exclusion criterion : 1 . Patients receive one prior line chemotherapy ( i.e. , second third line chemotherapy ) advance metastatic NSCLC ( Prior monotherapies epidermal growth factor receptor tyrosine kinase inhibitor [ EGFRTKI ] ) anaplastic lymphoma kinase ( ALK ) inhibitor allow ) 2 . Patients receive previous therapy vascular endothelial growth factor ( VEGF ) vascular endothelial growth factor receptor ( VEGFR ) inhibitor ( bevacizumab ) treatment NSCLC time 3 . Patients receive follow treatment within 4 week prior start study therapy 1 ) Other investigational drug 2 ) Chemo , hormone , immunotherapy , monoclonal antibody . 4 . Patients receive molecular target therapy include EGFR TKIs ALK inhibitor within 2 week prior start study therapy 5 . Patents receive radiotherapy within past 3 month ( case limit field [ e.g . brain bone metastasis ] radiotherapy palliative intent ) , within 2 week ) prior start study therapy 6 . Patients recover clinically relevant therapy relate toxicity previous chemotherapy and/or radiotherapy ( =CTCAE grade 2 AE previous treatment ) screen exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>